Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
What You Missed On Wall Street This Morning » 12:16
02/01/23
02/01
12:16
02/01/23
12:16
SNAP

Snap

$9.94 /

-1.6 (-13.86%)

, AMD

AMD

$81.11 /

+5.92 (+7.87%)

, TMUS

T-Mobile

$151.42 /

+2.03 (+1.36%)

, WDC

Western Digital

$42.05 /

-1.88 (-4.28%)

, EA

Electronic Arts

$113.11 /

-15.38 (-11.97%)

, FL

Foot Locker

$44.72 /

+1.22 (+2.80%)

, FNKO

Funko

$11.14 /

-0.97 (-8.01%)

, MSFT

Microsoft

$247.03 /

-0.89 (-0.36%)

, NFLX

Netflix

$356.70 /

+2.98 (+0.84%)

, META

Meta Platforms

$148.79 /

-0.17 (-0.11%)

, AAPL

Apple

$142.39 /

-1.88 (-1.30%)

, RPD

Rapid7

$48.79 /

+8.93 (+22.40%)

, MVIS

MicroVision

$2.75 /

+0.225 (+8.93%)

, WRK

WestRock

$33.44 /

-5.82 (-14.82%)

, HA

Hawaiian Holdings

$10.62 /

-1.705 (-13.84%)

, APPS

Digital Turbine

$15.98 /

-1.38 (-7.95%)

, BFH

Bread Financial

$37.56 /

-3.49 (-8.50%)

, SYF

Synchrony

$34.61 /

-2.11 (-5.75%)

, COF

Capital One

$115.63 /

-3.35 (-2.82%)

, MTCH

Match Group

$48.98 /

-5.095 (-9.42%)

, PTON

Peloton

$15.36 /

+2.445 (+18.93%)

, MO

Altria Group

$47.10 /

+2.05 (+4.55%)

, TMO

Thermo Fisher

$582.82 /

+12.68 (+2.22%)

, NVS

Novartis

$87.56 /

-3.05 (-3.37%)

, MRCY

Mercury Systems

$56.50 /

+6.4 (+12.77%)

Get caught up quickly on…

ShowHide Related Items >><<
WRK WestRock
$33.44 /

-5.82 (-14.82%)

WDC Western Digital
$42.05 /

-1.88 (-4.28%)

TMUS T-Mobile
$151.42 /

+2.03 (+1.36%)

TMO Thermo Fisher
$582.82 /

+12.68 (+2.22%)

SYF Synchrony
$34.61 /

-2.11 (-5.75%)

SNAP Snap
$9.94 /

-1.6 (-13.86%)

RPD Rapid7
$48.79 /

+8.93 (+22.40%)

PTON Peloton
$15.36 /

+2.445 (+18.93%)

NVS Novartis
$87.56 /

-3.05 (-3.37%)

NFLX Netflix
$356.70 /

+2.98 (+0.84%)

MVIS MicroVision
$2.75 /

+0.225 (+8.93%)

MTCH Match Group
$48.98 /

-5.095 (-9.42%)

MSFT Microsoft
$247.03 /

-0.89 (-0.36%)

MRCY Mercury Systems
$56.50 /

+6.4 (+12.77%)

MO Altria Group
$47.10 /

+2.05 (+4.55%)

META Meta Platforms
$148.79 /

-0.17 (-0.11%)

HA Hawaiian Holdings
$10.62 /

-1.705 (-13.84%)

FNKO Funko
$11.14 /

-0.97 (-8.01%)

FL Foot Locker
$44.72 /

+1.22 (+2.80%)

EA Electronic Arts
$113.11 /

-15.38 (-11.97%)

COF Capital One
$115.63 /

-3.35 (-2.82%)

BFH Bread Financial
$37.56 /

-3.49 (-8.50%)

APPS Digital Turbine
$15.98 /

-1.38 (-7.95%)

AMD AMD
$81.11 /

+5.92 (+7.87%)

AAPL Apple
$142.39 /

-1.88 (-1.30%)

SNAP Snap
$9.94 /

-1.6 (-13.86%)

02/01/23 Truist
Snap price target lowered to $8 from $10 at Truist
02/01/23 Rosenblatt
Snap price target raised to $10 from $8 at Rosenblatt
02/01/23 Canaccord
Snap price target lowered to $11 from $12 at Canaccord
02/01/23 Benchmark
Benchmark downgrades 'too far behind' Snap to Hold after earnings
AMD AMD
$81.11 /

+5.92 (+7.87%)

02/01/23 Craig-Hallum
Craig-Hallum downgrades AMD to Hold on slowing growth
02/01/23 Northland
AMD guidance 'isn't great,' but 'not a disaster,' says Northland
02/01/23 Craig-Hallum
AMD downgraded to Hold from Buy at Craig-Hallum
02/01/23 Morgan Stanley
AMD's softer outlook 'still could be a relief' after Intel, says Morgan Stanley
TMUS T-Mobile
$151.42 /

+2.03 (+1.36%)

01/17/23 KeyBanc
Cogent price target raised to $71 from $64 at KeyBanc
01/13/23 Truist
American Tower price target lowered to $275 from $325 at Truist
01/05/23 JPMorgan
T-Mobile remains a top pick after preannouncement at JPMorgan
01/03/23 Wolfe Research
T-Mobile downgraded to Peer Perform from Outperform at Wolfe Research
WDC Western Digital
$42.05 /

-1.88 (-4.28%)

02/01/23 Craig-Hallum
Western Digital price target raised to $60 from $50 at Craig-Hallum
02/01/23 Mizuho
Western Digital price target lowered to $35 from $38 at Mizuho
01/23/23 Exane BNP Paribas
Western Digital upgraded to Neutral from Underperform at Exane BNP Paribas
01/06/23 Benchmark
Western Digital upgraded to Hold at Benchmark after Kioxia merger talks report
EA Electronic Arts
$113.11 /

-15.38 (-11.97%)

02/01/23 BofA
Electronic Arts downgraded to Neutral at BofA on lower growth outlook
02/01/23 BofA
Electronic Arts downgraded to Neutral from Buy at BofA
02/01/23 Wells Fargo
Electronic Arts price target lowered to $120 from $150 at Wells Fargo
02/01/23 Roth MKM
Electronic Arts price target lowered to $112 from $131 at Roth Capital
FL Foot Locker
$44.72 /

+1.22 (+2.80%)

02/01/23 Credit Suisse
Foot Locker upgraded to Outperform from Neutral at Credit Suisse
11/28/22 Goldman Sachs
Goldman finds small crowds, more promotions over Black Friday weekend
11/21/22 Barclays
Foot Locker price target raised to $40 from $38 at Barclays
11/21/22 Deutsche Bank
Foot Locker price target raised to $36 from $31 at Deutsche Bank
FNKO Funko
$11.14 /

-0.97 (-8.01%)

01/31/23 Goldman Sachs
Goldman assumes Funko, downgrades to Sell on execution risk
01/31/23 Goldman Sachs
Funko downgraded to Sell from Neutral at Goldman Sachs
01/12/23 Jefferies
Funko downgraded to Hold from Buy at Jefferies
01/04/23 BMO Capital
Funko likely had 'decent holiday', says BMO Capital
MSFT Microsoft
$247.03 /

-0.89 (-0.36%)

01/27/23 BMO Capital
SAP price target raised to $125 from $110 at BMO Capital
01/27/23 Wedbush
Activision Blizzard assumed with an Outperform at Wedbush
01/26/23 Credit Suisse
Microsoft price target lowered to $285 from $365 at Credit Suisse
01/26/23 Oppenheimer
Alphabet price target lowered to $130 from $135 at Oppenheimer
NFLX Netflix
$356.70 /

+2.98 (+0.84%)

01/26/23
Netflix downgraded to Accumulate from Buy at Phillip Securities
01/23/23 Argus
Netflix price target raised to $390 from $340 at Argus
01/22/23 Citi
Netflix price target raised to $395 from $315 at Citi
01/20/23 Deutsche Bank
Netflix price target raised to $400 from $350 at Deutsche Bank
META Meta Platforms
$148.79 /

-0.17 (-0.11%)

01/31/23 LightShed Partners
Meta Platforms initiated with a Buy at LightShed Partners
01/30/23 DA Davidson
DA Davidson neutral on Pinterest ahead of earnings
01/27/23 BofA
BuzzFeed still a 'show me story,' Meta deal not new, says BofA
01/26/23 Piper Sandler
Meta Platforms price target raised to $136 from $116 at Piper Sandler
AAPL Apple
$142.39 /

-1.88 (-1.30%)

01/31/23 UBS
Apple iPhone sell-through down 12% in Q4, says UBS
01/30/23 Wells Fargo
Wells Fargo near-term cautious on Apple into upcoming Q1 earnings
01/30/23 Credit Suisse
Credit Suisse remains bullish on Apple, sees potential upside to estimates
RPD Rapid7
$48.79 /

+8.93 (+22.40%)

01/24/23 JPMorgan
Rapid7 initiated with a Neutral at JPMorgan
01/12/23 DA Davidson
Rapid7 initiated with a Neutral at DA Davidson
01/05/23 Piper Sandler
Rapid7 price target lowered to $45 from $50 at Piper Sandler
01/04/23 Barclays
Rapid7 downgraded to Equal Weight from Overweight at Barclays
MVIS MicroVision
$2.75 /

+0.225 (+8.93%)

03/07/22 Cantor Fitzgerald
MicroVision initiated with a Neutral at Cantor Fitzgerald
WRK WestRock
$33.44 /

-5.82 (-14.82%)

01/04/23 Citi
WestRock price target lowered to $37 from $39 at Citi
11/13/22 Citi
WestRock price target raised to $39 from $35 at Citi
11/11/22 Truist
WestRock price target lowered to $35 from $40 at Truist
10/18/22 Deutsche Bank
WestRock price target lowered to $37 from $45 at Deutsche Bank
HA Hawaiian Holdings
$10.62 /

-1.705 (-13.84%)

02/01/23 Cowen
Hawaiian Holdings price target lowered to $16 from $19 at Cowen
12/20/22 Deutsche Bank
Hawaiian Holdings price target lowered to $13 from $17 at Deutsche Bank
12/16/22 Goldman Sachs
Hawaiian Holdings resumed with a Sell at Goldman Sachs
10/06/22 BofA
Hawaiian Holdings price target lowered to $10 from $12 at BofA
APPS Digital Turbine
$15.98 /

-1.38 (-7.95%)

02/01/23 B. Riley
B. Riley downgrades Digital Turbine on app economy softness
02/01/23 B. Riley
Digital Turbine downgraded to Neutral from Buy at B. Riley
11/10/22 Craig-Hallum
Digital Turbine price target lowered to $30 from $60 at Craig-Hallum
10/31/22 Roth MKM
Digital Turbine price target lowered to $20 from $32 at Roth Capital
BFH Bread Financial
$37.56 /

-3.49 (-8.50%)

02/01/23 BTIG
CFPB credit card late fee proposal 'more onerous than expected,' says BTIG
01/26/23 Stephens
Stephens remains buyer of Bread Financial on weakness
01/05/23 Stephens
Stephens raises 'most conservative' card company Bread Financial to Overweight
01/05/23 Stephens
Bread Financial upgraded to Overweight from Equal Weight at Stephens
SYF Synchrony
$34.61 /

-2.11 (-5.75%)

02/01/23 Citi
Citi sees weakness in Synchrony after CFPB proposal as buying opportunity
01/24/23 BMO Capital
Synchrony price target lowered to $53 from $56 at BMO Capital
01/24/23 JMP Securities
Synchrony price target raised to $42 from $39 at JMP Securities
COF Capital One
$115.63 /

-3.35 (-2.82%)

01/25/23 BMO Capital
Capital One price target lowered to $141 from $152 at BMO Capital
01/25/23 JPMorgan
Capital One price target lowered to $120 from $124 at JPMorgan
MTCH Match Group
$48.98 /

-5.095 (-9.42%)

01/31/23 Piper Sandler
Match Group turnaround bumpier than hoped, says Piper Sandler
01/30/23 Deutsche Bank
Match Group price target raised to $65 from $60 at Deutsche Bank
01/26/23 Citi
Match Group initiated with a Neutral at Citi
01/25/23 Barclays
Match Group price target raised to $52 from $50 at Barclays
PTON Peloton
$15.36 /

+2.445 (+18.93%)

01/30/23 Citi
Peloton promotions drove improved traffic trends, says Citi
01/24/23 MKM Partners
MKM Partners positive on Peloton heading into earnings
01/24/23 Baird
Peloton downgraded to Neutral from Outperform at Baird
11/21/22 Cowen
Peloton downgraded to Market Perform from Outperform at Cowen
MO Altria Group
$47.10 /

+2.05 (+4.55%)

11/10/22 UBS
UBS downgrades Altria to Sell on consumer trade down risk
11/10/22 UBS
Altria Group downgraded to Sell from Neutral at UBS
11/02/22 Morgan Stanley
Philip Morris price target raised to $109 from $102 at Morgan Stanley
10/28/22 Stifel
Altria JV news trumps 'rare' EPS miss, says Stifel
TMO Thermo Fisher
$582.82 /

+12.68 (+2.22%)

01/24/23 Barclays
Thermo Fisher price target raised to $630 from $570 at Barclays
01/03/23 Wells Fargo
Thermo Fisher price target lowered to $505 from $525 at Wells Fargo
12/13/22 Deutsche Bank
Thermo Fisher initiated with a Buy at Deutsche Bank
12/06/22 RBC Capital
Thermo Fisher initiated with an Outperform at RBC Capital
NVS Novartis
$87.56 /

-3.05 (-3.37%)

01/26/23 Citi
Novartis downgraded to Neutral from Buy at Citi
01/24/23 Lake Street
Harrow Health price target raised to $24 from $17 at Lake Street
01/06/23 Morgan Stanley
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
01/03/23 JPMorgan
Novartis upgraded to Neutral from Underweight at JPMorgan
MRCY Mercury Systems
$56.50 /

+6.4 (+12.77%)

02/01/23 Jefferies
Mercury Systems unlikely to see interest from U.S. Primes, says Jefferies
12/16/22 RBC Capital
Mercury Systems downgraded to Sector Perform from Outperform at RBC Capital
10/27/22 Raymond James
Mercury Systems initiated with an Outperform at Raymond James
08/03/22 Alembic Global
Mercury Systems downgraded to Neutral from Overweight at Alembic Global
WRK WestRock
$33.44 /

-5.82 (-14.82%)

WDC Western Digital
$42.05 /

-1.88 (-4.28%)

TMUS T-Mobile
$151.42 /

+2.03 (+1.36%)

TMO Thermo Fisher
$582.82 /

+12.68 (+2.22%)

SYF Synchrony
$34.61 /

-2.11 (-5.75%)

SNAP Snap
$9.94 /

-1.6 (-13.86%)

RPD Rapid7
$48.79 /

+8.93 (+22.40%)

PTON Peloton
$15.36 /

+2.445 (+18.93%)

NVS Novartis
$87.56 /

-3.05 (-3.37%)

NFLX Netflix
$356.70 /

+2.98 (+0.84%)

MTCH Match Group
$48.98 /

-5.095 (-9.42%)

MSFT Microsoft
$247.03 /

-0.89 (-0.36%)

MRCY Mercury Systems
$56.50 /

+6.4 (+12.77%)

MO Altria Group
$47.10 /

+2.05 (+4.55%)

META Meta Platforms
$148.79 /

-0.17 (-0.11%)

HA Hawaiian Holdings
$10.62 /

-1.705 (-13.84%)

FNKO Funko
$11.14 /

-0.97 (-8.01%)

FL Foot Locker
$44.72 /

+1.22 (+2.80%)

EA Electronic Arts
$113.11 /

-15.38 (-11.97%)

COF Capital One
$115.63 /

-3.35 (-2.82%)

BFH Bread Financial
$37.56 /

-3.49 (-8.50%)

APPS Digital Turbine
$15.98 /

-1.38 (-7.95%)

AMD AMD
$81.11 /

+5.92 (+7.87%)

AAPL Apple
$142.39 /

-1.88 (-1.30%)

WDC Western Digital
$42.05 /

-1.88 (-4.28%)

TMUS T-Mobile
$151.42 /

+2.03 (+1.36%)

TMO Thermo Fisher
$582.82 /

+12.68 (+2.22%)

SYF Synchrony
$34.61 /

-2.11 (-5.75%)

SNAP Snap
$9.94 /

-1.6 (-13.86%)

RPD Rapid7
$48.79 /

+8.93 (+22.40%)

PTON Peloton
$15.36 /

+2.445 (+18.93%)

NVS Novartis
$87.56 /

-3.05 (-3.37%)

NFLX Netflix
$356.70 /

+2.98 (+0.84%)

MTCH Match Group
$48.98 /

-5.095 (-9.42%)

MSFT Microsoft
$247.03 /

-0.89 (-0.36%)

MRCY Mercury Systems
$56.50 /

+6.4 (+12.77%)

MO Altria Group
$47.10 /

+2.05 (+4.55%)

META Meta Platforms
$148.79 /

-0.17 (-0.11%)

FL Foot Locker
$44.72 /

+1.22 (+2.80%)

EA Electronic Arts
$113.11 /

-15.38 (-11.97%)

COF Capital One
$115.63 /

-3.35 (-2.82%)

AMD AMD
$81.11 /

+5.92 (+7.87%)

AAPL Apple
$142.39 /

-1.88 (-1.30%)

WDC Western Digital
$42.05 /

-1.88 (-4.28%)

TMUS T-Mobile
$151.42 /

+2.03 (+1.36%)

TMO Thermo Fisher
$582.82 /

+12.68 (+2.22%)

SYF Synchrony
$34.61 /

-2.11 (-5.75%)

SNAP Snap
$9.94 /

-1.6 (-13.86%)

RPD Rapid7
$48.79 /

+8.93 (+22.40%)

PTON Peloton
$15.36 /

+2.445 (+18.93%)

NVS Novartis
$87.56 /

-3.05 (-3.37%)

NFLX Netflix
$356.70 /

+2.98 (+0.84%)

MTCH Match Group
$48.98 /

-5.095 (-9.42%)

MSFT Microsoft
$247.03 /

-0.89 (-0.36%)

MRCY Mercury Systems
$56.50 /

+6.4 (+12.77%)

MO Altria Group
$47.10 /

+2.05 (+4.55%)

META Meta Platforms
$148.79 /

-0.17 (-0.11%)

HA Hawaiian Holdings
$10.62 /

-1.705 (-13.84%)

FNKO Funko
$11.14 /

-0.97 (-8.01%)

FL Foot Locker
$44.72 /

+1.22 (+2.80%)

EA Electronic Arts
$113.11 /

-15.38 (-11.97%)

COF Capital One
$115.63 /

-3.35 (-2.82%)

APPS Digital Turbine
$15.98 /

-1.38 (-7.95%)

AMD AMD
$81.11 /

+5.92 (+7.87%)

AAPL Apple
$142.39 /

-1.88 (-1.30%)

WDC Western Digital
$42.05 /

-1.88 (-4.28%)

TMUS T-Mobile
$151.42 /

+2.03 (+1.36%)

TMO Thermo Fisher
$582.82 /

+12.68 (+2.22%)

SYF Synchrony
$34.61 /

-2.11 (-5.75%)

SNAP Snap
$9.94 /

-1.6 (-13.86%)

PTON Peloton
$15.36 /

+2.445 (+18.93%)

NVS Novartis
$87.56 /

-3.05 (-3.37%)

NFLX Netflix
$356.70 /

+2.98 (+0.84%)

MVIS MicroVision
$2.75 /

+0.225 (+8.93%)

MTCH Match Group
$48.98 /

-5.095 (-9.42%)

MSFT Microsoft
$247.03 /

-0.89 (-0.36%)

MO Altria Group
$47.10 /

+2.05 (+4.55%)

META Meta Platforms
$148.79 /

-0.17 (-0.11%)

FL Foot Locker
$44.72 /

+1.22 (+2.80%)

EA Electronic Arts
$113.11 /

-15.38 (-11.97%)

COF Capital One
$115.63 /

-3.35 (-2.82%)

APPS Digital Turbine
$15.98 /

-1.38 (-7.95%)

AMD AMD
$81.11 /

+5.92 (+7.87%)

AAPL Apple
$142.39 /

-1.88 (-1.30%)

Earnings
Novartis sees core operating income to grow mid single digit percentage in 2023 » 08:31
02/01/23
02/01
08:31
02/01/23
08:31
NVS

Novartis

$90.61 /

+0.965 (+1.08%)

Novartis' 2023…

Novartis' 2023 guidance: "Group expected to grow sales low-to-mid single digit and core operating income mid single digit. IM expected to grow sales low-to-mid single digit and core operating income mid-to-high single digit." The company previously announced an up-to $15B share buyback is ongoing, noting that $4.9B is still to be executed. A dividend of CHF 3.20 per share, an increase of 3.2%, is proposed for 2022.

ShowHide Related Items >><<
NVS Novartis
$90.61 /

+0.965 (+1.08%)

NVS Novartis
$90.61 /

+0.965 (+1.08%)

01/26/23 Citi
Novartis downgraded to Neutral from Buy at Citi
01/24/23 Lake Street
Harrow Health price target raised to $24 from $17 at Lake Street
01/06/23 Morgan Stanley
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
01/03/23 JPMorgan
Novartis upgraded to Neutral from Underweight at JPMorgan
NVS Novartis
$90.61 /

+0.965 (+1.08%)

NVS Novartis
$90.61 /

+0.965 (+1.08%)

NVS Novartis
$90.61 /

+0.965 (+1.08%)

NVS Novartis
$90.61 /

+0.965 (+1.08%)

Earnings
Novartis reports Q4 core EPS $1.52, consensus $1.44 » 08:29
02/01/23
02/01
08:29
02/01/23
08:29
NVS

Novartis

$90.61 /

+0.965 (+1.08%)

Reports Q4 revenue…

Reports Q4 revenue $12.69B, consensus $13.13B. Commenting on 2022 results, Vas Narasimhan, CEO of Novartis, said: "Novartis is on track to become a pure-play innovative medicines company, uniquely positioned to leverage its global scale and R&D platforms. Our six multi-billion brands now represent 32% of our Innovative Medicines sales and are growing 26%. Pluvicto and Scemblix had very strong launch performances, and the Leqvio launch continues to progress. Pivotal Ph3 readouts for two iptacopan studies and Pluvicto in earlier lines of therapy provide strong confidence for near to mid-term growth. Looking ahead, we have a catalyst rich pipeline with 15 pivotal readouts in the mid-term. We expect to continue to deliver improved financials and strengthen Novartis ESG foundations, on our journey to become most trusted and valued medicines company in the world."

ShowHide Related Items >><<
NVS Novartis
$90.61 /

+0.965 (+1.08%)

NVS Novartis
$90.61 /

+0.965 (+1.08%)

01/26/23 Citi
Novartis downgraded to Neutral from Buy at Citi
01/24/23 Lake Street
Harrow Health price target raised to $24 from $17 at Lake Street
01/06/23 Morgan Stanley
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
01/03/23 JPMorgan
Novartis upgraded to Neutral from Underweight at JPMorgan
NVS Novartis
$90.61 /

+0.965 (+1.08%)

NVS Novartis
$90.61 /

+0.965 (+1.08%)

NVS Novartis
$90.61 /

+0.965 (+1.08%)

NVS Novartis
$90.61 /

+0.965 (+1.08%)

Hot Stocks
CureVac appoints Myriam Mendila as CDO » 07:29
02/01/23
02/01
07:29
02/01/23
07:29
CVAC

CureVac

$10.73 /

-0.87 (-7.50%)

, NVS

Novartis

$90.61 /

+0.965 (+1.08%)

CureVac (CVAC) announced…

CureVac (CVAC) announced that Myriam Mendila has taken up her role as CureVac's Chief Development Officer, as previously announced. Over the last 5 years, she has held the position of Chief Medical Officer Oncology and Global Head of Oncology Medical Affairs at Novartis, being responsible for the Medical Affairs strategy and related activities across the overall oncology portfolio at Novartis (NVS).

ShowHide Related Items >><<
NVS Novartis
$90.61 /

+0.965 (+1.08%)

CVAC CureVac
$10.73 /

-0.87 (-7.50%)

CVAC CureVac
$10.73 /

-0.87 (-7.50%)

01/30/23 JMP Securities
JMP Securities says older-adult update continues to look encouraging for CureVac
01/19/23 UBS
UBS upgrades CureVac after 'major milestone and clearing event'
01/19/23 UBS
CureVac upgraded to Buy from Neutral at UBS
01/09/23 Jefferies
CureVac upgraded to Buy at Jefferies after mRNA platform validation
NVS Novartis
$90.61 /

+0.965 (+1.08%)

01/26/23 Citi
Novartis downgraded to Neutral from Buy at Citi
01/24/23 Lake Street
Harrow Health price target raised to $24 from $17 at Lake Street
01/06/23 Morgan Stanley
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
01/03/23 JPMorgan
Novartis upgraded to Neutral from Underweight at JPMorgan
NVS Novartis
$90.61 /

+0.965 (+1.08%)

CVAC CureVac
$10.73 /

-0.87 (-7.50%)

NVS Novartis
$90.61 /

+0.965 (+1.08%)

NVS Novartis
$90.61 /

+0.965 (+1.08%)

CVAC CureVac
$10.73 /

-0.87 (-7.50%)

NVS Novartis
$90.61 /

+0.965 (+1.08%)

Monday
Hot Stocks
Novartis' Sandoz receives positive CHMP opinion for citrate-free HCF adalimumab » 07:03
01/30/23
01/30
07:03
01/30/23
07:03
NVS

Novartis

$89.49 /

-0.355 (-0.40%)

Novartis' Sandoz…

Novartis' Sandoz announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion for marketing authorization for a citrate-free high concentration formulation, or HCF, of its biosimilar Hyrimoz, or adalimumab. The authorization includes all indications covered by the reference medicine: rheumatoid arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis and uveitis. "Upon approval, the adalimumab citrate-free HCF (100 mg/mL) formulation will offer reduced injection volume and potentially decrease the number of injections required for patients who need 80 mg/mL dosing. The HCF formulation will have the same auto-injector as currently offered, aiming for an enhanced yet familiar patient experience," the company stated.

ShowHide Related Items >><<
NVS Novartis
$89.49 /

-0.355 (-0.40%)

NVS Novartis
$89.49 /

-0.355 (-0.40%)

01/26/23 Citi
Novartis downgraded to Neutral from Buy at Citi
01/24/23 Lake Street
Harrow Health price target raised to $24 from $17 at Lake Street
01/06/23 Morgan Stanley
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
01/03/23 JPMorgan
Novartis upgraded to Neutral from Underweight at JPMorgan
NVS Novartis
$89.49 /

-0.355 (-0.40%)

NVS Novartis
$89.49 /

-0.355 (-0.40%)

NVS Novartis
$89.49 /

-0.355 (-0.40%)

NVS Novartis
$89.49 /

-0.355 (-0.40%)

Over a week ago
Downgrade
Novartis downgraded to Neutral from Buy at Citi » 04:31
01/26/23
01/26
04:31
01/26/23
04:31
NVS

Novartis

$92.81 /

+0.775 (+0.84%)

, NVO

Novo Nordisk

$138.94 /

-1.06 (-0.76%)

, AZN

AstraZeneca

$66.62 /

+0.335 (+0.51%)

, MRK

Merck

$108.60 /

+0.065 (+0.06%)

, RHHBY

Roche

$40.05 /

+0.1 (+0.25%)

Citi analyst Andrew Baum…

Citi analyst Andrew Baum downgraded Novartis (NVS) to Neutral from Buy with a CHF 86 price target. The shares have outperformed all European pharma majors except Novo Nordisk (NVO) and AstraZeneca (AZN) due to the impact of management action in the last six months, aided by some rotation out of Roche (RHHBY), the analyst tells investors in a research note. Citi reduced Novartis earnings estimates to by up to 8% to reflect a more cautious outlook for Leqvio given competitive pressures from Merck's (MRK) oral PCSK-9 MK-0616 in the U.S. commercial and outside the U.S. market. The firm also highlights material ongoing supply constraints hindering Pluvicto's U.S. launch in prostate cancer.

ShowHide Related Items >><<
RHHBY Roche
$40.05 /

+0.1 (+0.25%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

01/24/23 Lake Street
Harrow Health price target raised to $24 from $17 at Lake Street
01/06/23 Morgan Stanley
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
01/03/23 JPMorgan
Novartis upgraded to Neutral from Underweight at JPMorgan
12/14/22 UBS
Novartis price target raised to CHF 84 from CHF 82 at UBS
NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

01/18/23 Deutsche Bank
Deutsche Bank bearish on Roche heading into FY23, cuts to Sell
01/03/23 JPMorgan
Novo Nordisk price target raised to DKK 1,100 from DKK 925 at JPMorgan
01/03/23 JPMorgan
Novo Nordisk added to Analyst Focus List at JPMorgan
12/12/22 Cowen
Novo Nordisk price target raised to $145 from $130 at Cowen
AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

01/18/23 Berenberg
AstraZeneca price target raised to 126 GBp from 118 GBp at Berenberg
01/12/23 Guggenheim
Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
01/12/23 Barclays
CinCor Pharma downgraded to Equal Weight from Overweight at Barclays
01/05/23 BMO Capital
AstraZeneca initiated with an Outperform at BMO Capital
MRK Merck
$108.60 /

+0.065 (+0.06%)

01/04/23 BofA
Merck upgraded to Buy at BofA on consistent revenue upside
01/04/23 BofA
Merck upgraded to Buy from Neutral at BofA
01/03/23 Wells Fargo
Merck price target raised to $125 from $110 at Wells Fargo
01/03/23 Cowen
Merck price target raised to $120 from $108 at Cowen
RHHBY Roche
$40.05 /

+0.1 (+0.25%)

01/24/23 Evercore ISI
TG Therapeutics price target raised to $25 from $16 at Evercore ISI
01/18/23 Deutsche Bank
Roche downgraded to Sell from Hold at Deutsche Bank
RHHBY Roche
$40.05 /

+0.1 (+0.25%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

RHHBY Roche
$40.05 /

+0.1 (+0.25%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

RHHBY Roche
$40.05 /

+0.1 (+0.25%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

Recommendations
Harrow Health price target raised to $24 from $17 at Lake Street » 09:21
01/24/23
01/24
09:21
01/24/23
09:21
HROW

Harrow Health

$14.18 /

-0.19 (-1.32%)

, NVS

Novartis

$92.22 /

+0.165 (+0.18%)

Lake Street analyst…

Lake Street analyst Brooks O'Neil raised the firm's price target on Harrow Health (HROW) to $24 from $17 and keeps a Buy rating on the shares after Harrow completed the acquisition of the exclusive U.S. commercial rights to five branded ophthalmic products from Novartis (NVS) and affirmed 2023 guidance. Given the new rights along with fortisite and atropine, the "table is set for big things" from Harrow in 2023, Lake Street tells investors.

ShowHide Related Items >><<
NVS Novartis
$92.22 /

+0.165 (+0.18%)

HROW Harrow Health
$14.18 /

-0.19 (-1.32%)

HROW Harrow Health
$14.18 /

-0.19 (-1.32%)

01/05/23 B. Riley
Harrow Health price target raised to $22 from $17 at B. Riley
10/03/22 Lake Street
Lake Street affirms Buy rating on Harrow Health after 'big' week
09/08/22 B. Riley
Harrow Health resumed with a Buy at B. Riley
05/20/22 B. Riley
Harrow Health price target raised to $20 from $17 at B. Riley
NVS Novartis
$92.22 /

+0.165 (+0.18%)

01/06/23 Morgan Stanley
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
01/03/23 JPMorgan
Novartis upgraded to Neutral from Underweight at JPMorgan
12/14/22 UBS
Novartis price target raised to CHF 84 from CHF 82 at UBS
12/05/22 Stifel
Novartis upgraded to Buy from Hold at Stifel
NVS Novartis
$92.22 /

+0.165 (+0.18%)

HROW Harrow Health
$14.18 /

-0.19 (-1.32%)

  • 14
    Dec
NVS Novartis
$92.22 /

+0.165 (+0.18%)

NVS Novartis
$92.22 /

+0.165 (+0.18%)

HROW Harrow Health
$14.18 /

-0.19 (-1.32%)

NVS Novartis
$92.22 /

+0.165 (+0.18%)

Hot Stocks
Novartis unit Sandoz to acquire Mycamine from Astellas » 19:19
01/23/23
01/23
19:19
01/23/23
19:19
ALPMY

Astellas Pharma

$15.08 /

-0.18 (-1.18%)

, NVS

Novartis

$92.22 /

+0.165 (+0.18%)

Novartis (NVS) unit…

Novartis (NVS) unit Sandoz "has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine - micafungin sodium, Funguard - in Japan from Astellas (ALPMY). Closing is anticipated in the course of the first half of 2023. Mycamine is a leading global echinocandin, one of three major classes of antifungal agents, with a global patient base of well over two million. It is a therapy of choice in hospitals and intensive care units worldwide, a proven prophylactic in hematology and oncology patients, and widely used in organ transplants. Mycamine is indicated for treatment of invasive candidiasis and espophageal candidiasis, which are currently both on the rise with a higher occurrence of associated hospital outbreaks, as well as prevention of candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation. Astellas reported Mycamine sales of JPY 18.9 billion ($135M) for the year ending March 31, 2022."

ShowHide Related Items >><<
NVS Novartis
$92.22 /

+0.165 (+0.18%)

ALPMY Astellas Pharma
$15.08 /

-0.18 (-1.18%)

ALPMY Astellas Pharma
$15.08 /

-0.18 (-1.18%)

11/10/22 BTIG
Taysha Gene Therapies price target lowered to $15 from $25 at BTIG
11/09/22 Truist
Taysha cash overhang removed after Astellas investment, says Truist
10/26/22 Truist
Taysha Gene Therapies price target lowered to $15 from $35 at Truist
08/10/22 Citi
Astellas Pharma downgraded to Neutral from Buy at Citi
NVS Novartis
$92.22 /

+0.165 (+0.18%)

01/06/23 Morgan Stanley
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
01/03/23 JPMorgan
Novartis upgraded to Neutral from Underweight at JPMorgan
12/14/22 UBS
Novartis price target raised to CHF 84 from CHF 82 at UBS
12/05/22 Stifel
Novartis upgraded to Buy from Hold at Stifel
NVS Novartis
$92.22 /

+0.165 (+0.18%)

NVS Novartis
$92.22 /

+0.165 (+0.18%)

ALPMY Astellas Pharma
$15.08 /

-0.18 (-1.18%)

NVS Novartis
$92.22 /

+0.165 (+0.18%)

ALPMY Astellas Pharma
$15.08 /

-0.18 (-1.18%)

NVS Novartis
$92.22 /

+0.165 (+0.18%)

On The Fly
Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover » 13:02
01/12/23
01/12
13:02
01/12/23
13:02
ZVSA

ZyVersa Therapeutics

$1.87 /

-0.11 (-5.56%)

, MRK

Merck

$111.84 /

+0.79 (+0.71%)

, NVS

Novartis

$90.60 /

+0.165 (+0.18%)

, RHHBY

Roche

$39.02 /

-0.54 (-1.37%)

In an exclusive interview…

ShowHide Related Items >><<
ZVSA ZyVersa Therapeutics
$1.87 /

-0.11 (-5.56%)

RHHBY Roche
$39.02 /

-0.54 (-1.37%)

NVS Novartis
$90.60 /

+0.165 (+0.18%)

MRK Merck
$111.84 /

+0.79 (+0.71%)

ZVSA ZyVersa Therapeutics
$1.87 /

-0.11 (-5.56%)

MRK Merck
$111.84 /

+0.79 (+0.71%)

01/04/23 BofA
Merck upgraded to Buy at BofA on consistent revenue upside
01/04/23 BofA
Merck upgraded to Buy from Neutral at BofA
01/03/23 Wells Fargo
Merck price target raised to $125 from $110 at Wells Fargo
01/03/23 Cowen
Merck price target raised to $120 from $108 at Cowen
NVS Novartis
$90.60 /

+0.165 (+0.18%)

01/06/23 Morgan Stanley
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
01/03/23 JPMorgan
Novartis upgraded to Neutral from Underweight at JPMorgan
12/14/22 UBS
Novartis price target raised to CHF 84 from CHF 82 at UBS
12/05/22 Stifel
Novartis upgraded to Buy from Hold at Stifel
RHHBY Roche
$39.02 /

-0.54 (-1.37%)

01/12/23 Guggenheim
Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
01/05/23 Jefferies
Roche downgraded on 'tougher 2023 catalyst path' at Jefferies
01/04/23 Jefferies
Roche downgraded to Hold from Buy at Jefferies
01/03/23 JPMorgan
Roche downgraded to Underweight from Neutral at JPMorgan
RHHBY Roche
$39.02 /

-0.54 (-1.37%)

NVS Novartis
$90.60 /

+0.165 (+0.18%)

MRK Merck
$111.84 /

+0.79 (+0.71%)

RHHBY Roche
$39.02 /

-0.54 (-1.37%)

NVS Novartis
$90.60 /

+0.165 (+0.18%)

MRK Merck
$111.84 /

+0.79 (+0.71%)

ZVSA ZyVersa Therapeutics
$1.87 /

-0.11 (-5.56%)

RHHBY Roche
$39.02 /

-0.54 (-1.37%)

NVS Novartis
$90.60 /

+0.165 (+0.18%)

MRK Merck
$111.84 /

+0.79 (+0.71%)

NVS Novartis
$90.60 /

+0.165 (+0.18%)

MRK Merck
$111.84 /

+0.79 (+0.71%)

Options
Novartis call volume above normal and directionally bullish » 11:45
01/09/23
01/09
11:45
01/09/23
11:45
NVS

Novartis

$92.95 /

+0.66 (+0.72%)

Bullish option flow…

Bullish option flow detected in Novartis with 7,664 calls trading, 5x expected, and implied vol increasing over 5 points to 22.66%. Jan-23 95 calls and Jan-23 92.5 calls are the most active options, with total volume in those strikes near 6,400 contracts. The Put/Call Ratio is 0.26. Earnings are expected on February 1st.

ShowHide Related Items >><<
NVS Novartis
$92.95 /

+0.66 (+0.72%)

NVS Novartis
$92.95 /

+0.66 (+0.72%)

01/06/23 Morgan Stanley
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
01/03/23 JPMorgan
Novartis upgraded to Neutral from Underweight at JPMorgan
12/14/22 UBS
Novartis price target raised to CHF 84 from CHF 82 at UBS
12/05/22 Stifel
Novartis upgraded to Buy from Hold at Stifel
NVS Novartis
$92.95 /

+0.66 (+0.72%)

NVS Novartis
$92.95 /

+0.66 (+0.72%)

NVS Novartis
$92.95 /

+0.66 (+0.72%)

NVS Novartis
$92.95 /

+0.66 (+0.72%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.